Detalles de la búsqueda
1.
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study.
Oncologist
; 29(3): e372-e381, 2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37796838
2.
Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.
Anticancer Drugs
; 35(6): 559-562, 2024 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38453158
3.
Small cell lung cancer: Novel treatments beyond immunotherapy.
Semin Cancer Biol
; 86(Pt 2): 376-385, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35568295
4.
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 382(1): 41-50, 2020 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31751012
5.
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors.
Cancer Immunol Immunother
; 72(7): 2127-2135, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36828963
6.
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study.
Cancer Immunol Immunother
; 72(11): 3707-3716, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37638980
7.
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Future Oncol
; 19(1): 61-75, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36656302
8.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother
; 71(4): 865-874, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34462870
9.
A phase II, open-label, single-arm trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale.
Future Oncol
; 18(7): 771-779, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35068173
10.
Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study.
Pathologica
; 114(4): 278-287, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36083243
11.
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 22(10): 1438-1447, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34499874
12.
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2027-2039, 2018 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30280657
13.
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib.
Anticancer Drugs
; 32(7): 758-762, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33675607
14.
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios.
Mol Biol Rep
; 48(4): 3485-3494, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33856606
15.
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.
Curr Treat Options Oncol
; 22(11): 96, 2021 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34524570
16.
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients.
Future Oncol
; 17(9): 1097-1104, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33538178
17.
Pneumothorax and pulmonary hemorrhage after CT-guided lung biopsy: incidence, clinical significance and correlation.
Radiol Med
; 126(1): 170-177, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32377914
18.
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Lancet Oncol
; 21(7): 914-922, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32539942
19.
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Br J Cancer
; 123(1): 26-32, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32346071
20.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32474768